Overview

Pharmacokinetic Study of Palifermin in Subjects Receiving Radiation Therapy and Chemotherapy Followed by Blood Stem Cell Support

Status:
Completed

Trial end date:
2005-03-01

Target enrollment:

Participant gender:

Summary

Open label palifermin will be administered to subjects who are at a risk of developing mucositis after radiotherapy and chemotherapy followed by blood stem cell support. The amount of palifermin in the blood following administration will be evaluated. The safety of palifermin administration and its effect on reducing mucositis will also be evaluated.

Phase:

Phase 1

Details

Lead Sponsor:

Swedish Orphan Biovitrum

Collaborator:

Amgen